Results 1 to 10 of about 518 (110)
The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases
Current Issues in Molecular Biology, 2022 IL-17 inhibitors (IL-17i) are medicines used to treat dermatological and rheumatic diseases They belong to a class of medicines called biological disease-modifying anti-rheumatic drugs (bDMARDs).
Laura Țiburcă +6 more
doaj +3 more sources
Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management
Mycology, 2023 The application of interleukin-17 (IL-17) inhibitors, including secukinumab, ixekizumab, brodalumab, and bimekizumab, are associated with elevated risk of candidiasis. These medications interfere with the IL-17 pathway, which is essential for maintaining
Hazrat Bilal +17 more
doaj +3 more sources
Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors [PDF]
Drugs in Context, 2020 Background: Interleukin 17 (IL-17) inhibitors provide an excellent treatment option for patients with psoriasis and psoriatic arthritis, resulting in high levels of efficacy for skin clearance and joint improvement.
Keira A Fieldhouse +5 more
doaj +3 more sources
Научно-практическая ревматология, 2022 Objective – to compare the clinical efficacy and cost-effectiveness of IL-17 inhibitors (SEC, IXE, NTK) in the treatment of adult patients with ankylosing spondylitis (AS) in the healthcare system of the Russian Federation.Material and methods. The study
T. V. Dubinina +5 more
doaj +3 more sources
Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris [PDF]
Case Reports in Dermatology, 2019 We report two cases of alopecia diffusa during the treatment of psoriasis vulgaris with interleukin (IL)-17 inhibitors. Psoriasis is one of the most common immune-mediated chronic skin diseases, strongly associated with IL-17A. Clinically, the monoclonal
Makiko Yajima +4 more
doaj +3 more sources
Journal of Dermatological Treatment, 2023 Palmoplantar pustulosis (PPP) is a rare chronic pustular disease. Psoriatic arthritis (PsA) is one of the common manifestations of arthritis in PPP associated with a high burden of disease.
Zeng-Yun-Ou Zhang +3 more
doaj +3 more sources
A case report of recalcitrant aphthous ulcers in two patients treated with interleukin-17 inhibitors [PDF]
SAGE Open Medical Case Reports, 2021 The interleukin-17 signaling pathway plays a critical role in the pathogenesis of psoriasis. By inhibiting this pathway, there is a reduction in the severity of psoriasis and many patients achieve clear skin.
Madison Ward +2 more
doaj +3 more sources
Adverse Events and Immune Response in Psoriasis Patients Receiving Interleukin-17 Inhibitors
Acta Dermato-VenereologicaInterleukin-17 inhibitors are effective in psoriasis; however, they are associated with an increased risk of infections, particularly oral candidiasis, and new-onset/flares of inflammatory bowel disease.
Christopher Willy Schwarz +11 more
doaj +5 more sources
Pharmaceutics, 2023 Psoriasis is a chronic, inflammatory, multisystemic disease which affects approximately 2–3% of the population globally, whose onset is triggered by genetic and environmental factors which activate both dendritic cells and keratinocytes, resulting in the
Olguța Anca Orzan +9 more
doaj +1 more source
Научно-практическая ревматология, 2021 Netakimab is a humanized anti-interleukin-17А monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis.
T. V. Korotaeva +9 more
doaj +1 more source